Anti-HPLN4/ HAPLN4/ BRAL2 functional antibody

Anti-HPLN4/ HAPLN4/ BRAL2 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to HAPLN4/HAPLN4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0257-Ab-1/ GM-Tg-hg-SE0257-Ab-2Anti-Human HAPLN4 monoclonal antibodyHuman
GM-Tg-rg-SE0257-Ab-1/ GM-Tg-rg-SE0257-Ab-2Anti-Rat HAPLN4 monoclonal antibodyRat
GM-Tg-mg-SE0257-Ab-1/ GM-Tg-mg-SE0257-Ab-2Anti-Mouse HAPLN4 monoclonal antibodyMouse
GM-Tg-cynog-SE0257-Ab-1/ GM-Tg-cynog-SE0257-Ab-2Anti-Cynomolgus/ Rhesus macaque HAPLN4 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0257-Ab-1/ GM-Tg-felg-SE0257-Ab-2Anti-Feline HAPLN4 monoclonal antibodyFeline
GM-Tg-cang-SE0257-Ab-1/ GM-Tg-cang-SE0257-Ab-2Anti-Canine HAPLN4 monoclonal antibodyCanine
GM-Tg-bovg-SE0257-Ab-1/ GM-Tg-bovg-SE0257-Ab-2Anti-Bovine HAPLN4 monoclonal antibodyBovine
GM-Tg-equg-SE0257-Ab-1/ GM-Tg-equg-SE0257-Ab-2Anti-Equine HAPLN4 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0257-Ab-1/ GM-Tg-hg-SE0257-Ab-2; GM-Tg-rg-SE0257-Ab-1/ GM-Tg-rg-SE0257-Ab-2;
GM-Tg-mg-SE0257-Ab-1/ GM-Tg-mg-SE0257-Ab-2; GM-Tg-cynog-SE0257-Ab-1/ GM-Tg-cynog-SE0257-Ab-2;
GM-Tg-felg-SE0257-Ab-1/ GM-Tg-felg-SE0257-Ab-2; GM-Tg-cang-SE0257-Ab-1/ GM-Tg-cang-SE0257-Ab-2;
GM-Tg-bovg-SE0257-Ab-1/ GM-Tg-bovg-SE0257-Ab-2; GM-Tg-equg-SE0257-Ab-1/ GM-Tg-equg-SE0257-Ab-2
Products NameAnti-HAPLN4 monoclonal antibody
Formatmab
Target NameHAPLN4
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-HAPLN4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0257-Ag-1Recombinant multi-species HPLN4/ HAPLN4/ BRAL2 protein


    Target information

    Target IDGM-SE0257
    Target NameHAPLN4
    Gene ID404037,330790,361129,719748,100686618,101091262,539254,100146860
    Gene Symbol and Synonyms9330174O11,BRAL2,HAPLN4,Lpr4
    Uniprot AccessionQ86UW8
    Uniprot Entry NameHPLN4_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000187664
    Target ClassificationN/A

    The target: HAPLN4, gene name: HAPLN4, also named as BRAL2. Predicted to enable hyaluronic acid binding activity. Predicted to be involved in central nervous system development and skeletal system development. Predicted to be located in extracellular region. Predicted to be active in extracellular matrix. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.